In August 2018, the European Commission granted approval for the two chimeric antigen receptor (CAR) T-cell therapies – tisagenlecleucel and axicabtagene ciloleucel.36,37

Tisagenlecleucel is approved for use in pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant, or in second or later relapse. It is also approved to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received two or more lines of systemic therapy.29

Axicabtagene ciloleucel is approved for adults with relapsed/refractory DLBCL and primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy.38